<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study aimed to retrospectively evaluate the incidence of kerato-<z:hpo ids='HP_0000509'>conjunctivitis</z:hpo> in patients receiving TBI followed by high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, and to clarify how effectively topical <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> eye drops prevent kerato-<z:hpo ids='HP_0000509'>conjunctivitis</z:hpo> in these patients </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty-three patients who received <z:chebi fb="0" ids="28680">cytarabine</z:chebi> at a dose of 3 g/m2 every 12 h for 4 days after receiving TBI (12 Gy) as a conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) were evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>For the prophylaxis of kerato-<z:hpo ids='HP_0000509'>conjunctivitis</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo> patients received <z:chebi fb="0" ids="3078">betamethasone sodium phosphate</z:chebi> eye drops every 6 h, starting 1 day before the first dose of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and continuing until 1 day after the last dose of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> or the complete resolution of ocular symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>For grading of kerato-conjuncitivitis, the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute-Common Toxicity Criteria were used </plain></SENT>
<SENT sid="4" pm="."><plain>Among the 53 patients, the grades of kerato-<z:hpo ids='HP_0000509'>conjunctivitis</z:hpo> were grade 0 in 13 patients, grade 1 in 6 patients (11.3%), grade 2 in 10 patients (18.9%) and grade 3 in 25 patients (47.2%) </plain></SENT>
<SENT sid="5" pm="."><plain>These results strongly suggest that topical <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> eye drops could not effectively prevent the development of <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-induced kerato-<z:hpo ids='HP_0000509'>conjunctivitis</z:hpo> in HSCT recipients who receive high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> following TBI </plain></SENT>
<SENT sid="6" pm="."><plain>Further investigation into a more effective prophylaxis for <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-induced kerato-<z:hpo ids='HP_0000509'>conjunctivitis</z:hpo> in this setting is required </plain></SENT>
</text></document>